Onco Actu du 30 août 2017

	1. Biologie
Bowel cancer study reveals impact of mutations on protein networks [Sanger Institute] The results offer clearer picture of the cellular processes behind bowel cancer, and may enable future tailoring of drug treatments to different bowel cancer patients.
	3.1 Tabac
Leading Health Groups Demand Film Industry Give R-Rating to Movies that Depict Smoking [ACS] CDC estimates proposed R-rating would avert 1 million tobacco deaths among today’s children.
	3.1.1 Tabac - e-cigs
Fears over e-cigarettes leading to smoking for young people unfounded – study [The Guardian] Largest ever such survey of British 11- to 16-year-olds reveals experimentation with vaping devices does not translate into regular use and smoking rates still in decline.
	3.3 Prévention - Vaccins
HPV vaccination rates ticking upward, CDC says as it urges more uptake [FiercePharma] In an effort to boost rates, the CDC last year changed the HPV vaccination schedule from three doses to two for children 15 and under. Teens and young adults older than 15 still need three shots.
Adolescent and Young Adult Cancer Survivors Are Less Likely to Have HPV-Vaccination than Peers [ESMO] Treatment advances have resulted in a growing population of adolescent and young adult cancer survivors, which is the age-group at highest risk for sexually transmitted infection.
	3.8 Prévention - Alimentation
Huge new study casts doubt on conventional wisdom about fat and carbs [STAT] While most dietary guidelines stress the importance of eating more vegetables, among the PURE participants, eating more fruits, and more seeds and beans, was associated with greater benefits than eating more vegetables.
Life-saving fruit and vegetable diet need only be three portions – study [The Guardian] New research reveals daily dose of just 375g of fruit, vegetables and beans are sufficient to reduce risk of stroke, heart disease or premature death, and could help low-income consumers.
	4.12 Biopsies liquides
Detecting early signs of cancer in the blood [NIH] These findings suggest that circulating tumor DNA might be used to help detect early cancers and guide the care of cancer patients. More studies are needed in a larger number of people to validate whether this approach will be helpful in the clinic.
	5.12.1 Immunothérapies - partenariats
Five Prime cuts loose from InhibRx immuno-oncology deal [FierceBiotech] Five Prime paid $10 million upfront in July 2015 for the rights to the GITRs, proteins expressed by the body's T cells that it hoped would help stimulate an immune system attack on cancerous cells. Another $450 million plus—in cash or Five Prime stock—was dependent on progress with the program.
	5.12.5 Immunothérapies - Pharma
Celgene, Google double down on Armo’s PhIII immuno-oncology drug with $67M round [EndPoints] Armo, based in Redwood City, CA, has been working on new therapies that prime cancer cells for an immune assault. And it’s following up on its lead program with PD-1 and LAG-3 checkpoint therapies of their own, part of a major second wave of checkpoints that is now building behind the lead therapies to hit the market.
	5.12.8 Immunothérapies - Economie
How will Gilead price CAR-T? With Kite buy, the top biotech joins Novartis in spotlight [FiercePharma] In addition to urging fair prices for the U.S. public, KEI is also requesting Gilead license Kite's CAR-T patents to the Medicines Patent Pool to expand access in developing countries around the globe, Love said. Such an arrangement would require licensing partners to have expertise in CAR-T manufacturing, however.
Gilead’s $11.9 billion purchase of a groundbreaking cancer therapy could drag it into a new debate on prices [Washington Post] Brad Loncar, chief executive of an investment fund that focuses on cancer immunotherapy estimated the prices of CAR-T treatments might range from $300,000 to $500,000 — but argued that this class of drugs is exactly the kind of scientifically driven drug development that is worth the price.
Novartis CEO opens door to cancer patient demanding ‘fair’ CAR-T pricing [FiercePharma] Mitchell’s estimate that taxpayers funded $200 million worth of CAR-T research is based on a keyword search on the National Institutes of Health (NIH) website. Novartis’ academic partner, the University of Pennsylvania, got about $17 million of that. The rest went to the National Cancer Institute and more than 60 academic institutions and biotech companies.
	5.2 Pharma
U.S. FDA and European Medicines Agency Accept Regulatory Submissions for BOSULIF® (bosutinib) for the Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia [Pfizer] Applications seek to expand approved use of BOSULIF into first- line treatment based on positive results from Phase 3 head-to-head trial.
	5.2.1 Pharma - Partenariats
Jazz Pharma, ImmunoGen Strike Up Drug Pact in Leukemia and More [Xconomy] ImmunoGen develops antibody drug conjugates (ADC), which hitch a cancer-killing payload to an antibody, an approach that is meant to deliver a targeted strike to tumors that spares healthy tissue.
Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors [Genmab] Tisotumab vedotin, an antibody-drug conjugate (ADC) targeting tissue factor, is currently being evaluated in Phase I/II clinical studies in solid tumors. Going forward, Genmab and Seattle Genetics will co-develop and share all future costs and profits for tisotumab vedotin on a 50:50 basis.
Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort [EndPoints] They struck a deal giving Seattle Genetics an opt-in on tisotumab vedotin, now in several Phase I/II studies for solid tumors, including recurrent cervical cancer.
	5.2.2 Pharma - Fusions & Acquisitions
For Gilead Kite is no Pharmasset [EP Vantage] And while Gilead’s move clearly is not cheap – Kite has run up an accumulated deficit of under $500m since inception – cell therapy has simply become too important an area for the group not to be in.
	5.3 Traitements - FDA, EMA, NICE...
FDA targets rogue clinic using Sanofi's smallpox vaccine in unapproved cancer therapy [FiercePharma] Because the FDA is investigating the case, Sanofi said in a statement to FiercePharma that it can offer no further comment other than that it “remains fully committed to public health and the appropriate, safe and ethical use of its vaccines.”
Adverse Events: A Look Under the Hood [In the Pipeline] Can you use the FAERS data to mine out correlations that you didn’t know about before? From what I see in this paper, I’d advise caution.
Making Sense of FAERS: Researchers Suggest Fixes to FDA's Adverse Event Database [RAPS] One of the biggest factors that complicates research into FAERS data is the fact that many drug ingredients are sold under multiple names and in different formulations.
	5.6 ESMO
New Phase 3 Data for Abemaciclib and Ramucirumab Presented at ESMO 2017 Congress [Lilly] First presentations of MONARCH 3, a Phase 3 study of abemaciclib as initial treatment for advanced breast cancer, and RANGE, a Phase 3 study of ramucirumab for the treatment of platinum-refractory urothelial cancer.
	6. Lutte contre les cancers
NIH’s All of Us Research Program expands national network of medical centers [NIH] Awardees will help enroll participants in long-term precision medicine research effort.
Insights in Oncology: Burnout and the Specialty of Oncology [Clinical Oncology News] Despite the publication of thousands of articles describing the alarming statistics on burnout, there is very little being done by the oncology societies and hospital employers to address it.
Cancer patients lack access to fertility support [Reuters] For the new analysis, Dr. Shanna Logan at Kids Cancer Center, Sydney Children’s Hospital in Australia and colleagues examined data from 23 previous studies conducted in seven countries from 2007 to 2016.
	6.1 Observation
Why a growing number of women with breast cancer are choosing double mastectomy [STAT] The trend also seems to be U.S.-specific — Dr. Mehra Golshan, a breast cancer surgeon at Brigham and Women’s Hospital, recently ran a global trial on triple-negative breast cancer that found U.S. women were four times more likely to get a double mastectomy than women in Berlin or Seoul, South Korea.
	6.10 Politiques
UK report plans boost for life sciences as Brexit looms [Reuters] A government-commissioned sector report by immunologist and geneticist John Bell called on Wednesday for more funding of basic science, new incentives for manufacturing, and increased cooperation between drugmakers and the National Health Service (NHS).
	6.11 Patients
As cancer progresses some patients weep, some get angry and others are bewildered [The GUardian] Oncologists have to give bad news. But we can’t help it when our imaginations are held captive by a particular patient.
	6.5 Médecines alternatives
Cancer is ‘natural.’ The best treatments for it aren’t [STAT] It is human nature to believe that anything that is “all natural” is intrinsically good. That line of thought can lead people astray.
	6.6 Publications
Carlo Croce, OSU cancer researcher under investigation, retracts paper [Retraction Watch] Seven of his papers have now been retracted, and fourteen have been corrected for image and text issues such as manipulation, duplication, and errors, as well as two others earning expressions of concern.
Medical Journals Have a Fake News Problem [Bloomberg] With help from drug companies, Omics International is making millions as it roils the scientific community with sketchy publications.